214,288 Shares in Apyx Medical Corporation $APYX Acquired by Kingsview Wealth Management LLC

Kingsview Wealth Management LLC acquired a new stake in shares of Apyx Medical Corporation (NASDAQ:APYX) during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 214,288 shares of the company’s stock, valued at approximately $962,000. Kingsview Wealth Management LLC owned approximately 0.51% of Apyx Medical as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in APYX. Nwam LLC acquired a new stake in shares of Apyx Medical during the 1st quarter valued at $47,000. Citadel Advisors LLC acquired a new position in shares of Apyx Medical in the third quarter worth $28,000. Connor Clark & Lunn Investment Management Ltd. acquired a new position in shares of Apyx Medical in the second quarter worth $62,000. Hudson Bay Capital Management LP purchased a new stake in shares of Apyx Medical during the fourth quarter worth $73,000. Finally, Osaic Holdings Inc. purchased a new stake in shares of Apyx Medical during the second quarter worth $50,000. Hedge funds and other institutional investors own 55.33% of the company’s stock.

Apyx Medical Stock Performance

Shares of NASDAQ:APYX opened at $3.08 on Monday. The company has a current ratio of 5.68, a quick ratio of 4.53 and a debt-to-equity ratio of 3.19. The stock has a market capitalization of $129.73 million, a PE ratio of -15.40 and a beta of 1.39. Apyx Medical Corporation has a 1 year low of $1.70 and a 1 year high of $5.08. The firm has a fifty day moving average price of $3.87 and a 200 day moving average price of $3.84.

Apyx Medical (NASDAQ:APYX) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.08) by $0.01. The company had revenue of $13.88 million during the quarter, compared to the consensus estimate of $13.18 million. Apyx Medical had a negative return on equity of 76.60% and a negative net margin of 14.78%. Analysts expect that Apyx Medical Corporation will post -0.25 EPS for the current fiscal year.

Analysts Set New Price Targets

APYX has been the topic of a number of recent research reports. Zacks Research upgraded Apyx Medical to a “hold” rating in a research note on Tuesday, July 14th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Apyx Medical in a research note on Wednesday, June 24th. Finally, HC Wainwright started coverage on Apyx Medical in a report on Monday, July 13th. They set a “buy” rating and a $7.00 price target for the company. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Apyx Medical presently has a consensus rating of “Moderate Buy” and an average price target of $6.60.

Apyx Medical Company Profile

Apyx Medical (NASDAQ: APYX) is a medical device company focused on the development and commercialization of energy-based solutions for surgical and aesthetic applications. The company’s product portfolio includes devices that utilize radiofrequency energy, cold plasma and proprietary technologies designed to deliver precise thermal control and tissue treatment. Its key offerings encompass the J-Plasma technology under the Renuvion brand, which is primarily used for subdermal skin tightening and aesthetic procedures, and its portfolio of advanced energy medical devices for general surgery, gynecology and dermatology.

Leveraging its dual focus on surgical and aesthetic markets, Apyx Medical serves physicians and healthcare providers across North America, Europe and select international regions.